UroGen Pharma (URGN) EBT (2017 - 2026)
UroGen Pharma's (URGN) quarterly EBT came in at -$28.3 million in Q1 2026, up 34.76% YoY from -$21.0 million in Q1 2025, and down 6.41% on a QoQ basis from -$26.6 million in Q4 2025.
UroGen Pharma (URGN) EBT (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of EBT data on file, last reported at -$28.3 million in Q1 2026.
- Quarterly EBT rose 34.76% year-over-year to -$28.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$138.3 million (down 2.25% YoY) and the FY2025 annual result came in at -$153.4 million, down 23.68% from the prior year.
- EBT retreated to -$28.3 million in Q1 2026, from -$26.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$21.9 million in Q3 2023 to a low of -$48.9 million in Q2 2025.
- A 5-year average of -$30.1 million and a median of -$28.2 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT tumbled 57.31% — and 2026, when it surged 34.76%.
- Tracing URGN's EBT over 5 years: stood at -$28.2 million in 2022, then rose by 21.36% to -$22.2 million in 2023, then tumbled by 57.31% to -$34.9 million in 2024, then advanced by 23.59% to -$26.6 million in 2025, then decreased by 6.41% to -$28.3 million in 2026.
- The last three EBT figures came in at -$28.3 million (Q1 2026), -$26.6 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -8.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.72 Mn |
| Mar 31, 2026 | -28.35 Mn |
| Dec 31, 2025 | -26.64 Mn |
| Sep 30, 2025 | -34.40 Mn |
| Jun 30, 2025 | -48.93 Mn |
| Mar 31, 2025 | -43.45 Mn |
| Dec 31, 2024 | -34.86 Mn |
| Sep 30, 2024 | -23.58 Mn |
| Jun 30, 2024 | -33.37 Mn |
| Mar 31, 2024 | -32.23 Mn |
| Dec 31, 2023 | -22.16 Mn |
| Sep 30, 2023 | -21.89 Mn |
| Jun 30, 2023 | -24.08 Mn |
| Mar 31, 2023 | -30.19 Mn |
| Dec 31, 2022 | -28.18 Mn |
| Sep 30, 2022 | -25.12 Mn |
| Jun 30, 2022 | -26.66 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -27.32 Mn |
| Sep 30, 2021 | -30.21 Mn |